276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

Authors:
  • STS.M. Tolaney
    S.M. Tolaney
  • EAE. de Azambuja
    E. de Azambuja
  • LEL.A. Emens
    L.A. Emens
  • SLS. Loi
    S. Loi
  • WPW. Pan
    W. Pan
  • JHJ. Huang
    J. Huang
  • SSS.W. Sun
    S.W. Sun
  • CLC. Lai
    C. Lai
  • PSP. Schmid
    P. Schmid

Abstract
No abstract available